Enhanced Acquisition Opportunities Accelerates International Pre-IPO M&A StrategyMIAMI and NEW YORK and PARIS, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cyber A.I. Group, Inc. ("CyberAI" or the "Company"), an ...

KWESST Micro Systems Inc. (NASDAQ: KWE) (NASDAQ: KWESW) (TSXV: KWE) ("KWESST" or the "Company"), today announced the closing ...

Valens Semiconductor (NYSE:VLN – Get Free Report) will likely be issuing its quarterly earnings data before the market opens ...

NXXT after Closing of Share Exchange with Ezfill Holdings, Inc.MIAMI, Feb. 18, 2025 (GLOBE NEWSWIRE) -- NextNRG, Inc.

EzFill (EZFL) announced the pricing of a public offering of 5M shares of common stock at a price to the public of $3.00 per share, for gross ...

EzFill Holdings, Inc. ("EzFill" and the "Company") (Nasdaq: EZFL), a leading mobile fueling company, today announced the pricing of a public offering of 5,000 ...

ThinkEquity acted as sole placement agent for the offering. The securities were offered and sold pursuant to the Company’s effective shelf registration statement on Form S-3 (File No. 333-276650), ...

宾夕法尼亚州MALVERN - 目前股价接近52周低点2.99美元的临床阶段药物平台公司Annovis Bio Inc. (NYSE: ANVS)宣布启动其阿尔茨海默病 (AD)候选药物buntanetap的三期临床试验，首批两名患者已完成入组。根据InvestingPro数据显示，基于公平价值分析，该公司股票目前似乎被低估。该试验旨在评估buntanetap在早期AD患者中的安全性和有效性。

ThinkEquity acted as the sole book-running manager. To view the full press release, visit About Annovis Bio Inc. Annovis Bio, headquartered in Malvern, Pennsylvania, is committed to addressing ...

宾夕法尼亚州MALVERN - 专注于神经退行性疾病的临床阶段药物平台公司Annovis Bio, Inc. (NYSE: ANVS)已成功完成其公开发行，募集资金总额达2100万美元。此次发行包括525万股普通股和等量认股权证，每股和认股权证的组合价格为4.00美元。该公司股票目前交易价格为3.14美元，近期波动显著，过去一周下跌超过33%。根据 InvestingPro ...